Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.

Publication ,  Journal Article
Previs, R; Leath, CA; Coleman, RL; Herzog, TJ; Krivak, TC; Brower, SL; Tian, C; Secord, AA
Published in: Gynecol Oncol
August 2015

OBJECTIVE: Type I epithelial ovarian cancers (EOCs) are reported to be relatively chemoresistant. This study sought to compare pretreatment chemoresponse assays in Type I vs. Type II EOCs. STUDY DESIGN: 383 women with stage III-IV EOC enrolled in an observational study, with known chemoresponse assay results for 7 common therapeutic agents, were included. Type I EOCs were defined as grade 1 serous/endometrioid cancers and all clear cell/mucinous cancers. Type II EOCs were classified as grade 2-3 serous/endometrioid cancers and undifferentiated cancers. Chemotherapy assay responses were classified as sensitive (S), intermediately sensitive (I), or resistant (R). All patients were treated with platinum/taxane therapy following cytoreductive surgery. RESULTS: Thirty (7.8%) tumors were classified as Type I EOC, and 353 (92.2%) as Type II EOC. Type I patients were younger at the time of diagnosis (median age: 57 vs. 62 years, p=0.018) and had longer survival compared to Type II patients (mPFS: 25.8 vs. 16.4 months, HR=1.71, p=0.042). Eighty-six percent of Type I EOC specimens demonstrated a sensitive chemoresponse assay result to at least 1 agent; 35.7% were pan-S to all 7 agents. After adjusting for stage, debulking status, and type of EOC, multi-drug resistance was twice as likely in women with Type I EOC compared to Type II EOC (pan-R, 14.3% vs. 6.8% (p=0.268); pan-S, 35.7% vs. 51.2% (p=0.183)), but did not attain statistical significance. CONCLUSION(S): The majority of women with Type I EOC displayed assay sensitivity to at least one agent. Given the small sample size these findings need to be evaluated further.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

August 2015

Volume

138

Issue

2

Start / End Page

267 / 271

Location

United States

Related Subject Headings

  • Young Adult
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Female
  • Drug Resistance, Neoplasm
  • Drug Resistance, Multiple
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Previs, R., Leath, C. A., Coleman, R. L., Herzog, T. J., Krivak, T. C., Brower, S. L., … Secord, A. A. (2015). Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecol Oncol, 138(2), 267–271. https://doi.org/10.1016/j.ygyno.2015.05.038
Previs, Rebecca, Charles A. Leath, Robert L. Coleman, Thomas J. Herzog, Thomas C. Krivak, Stacey L. Brower, Chunqiao Tian, and Angeles Alvarez Secord. “Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.Gynecol Oncol 138, no. 2 (August 2015): 267–71. https://doi.org/10.1016/j.ygyno.2015.05.038.
Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, et al. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecol Oncol. 2015 Aug;138(2):267–71.
Previs, Rebecca, et al. “Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.Gynecol Oncol, vol. 138, no. 2, Aug. 2015, pp. 267–71. Pubmed, doi:10.1016/j.ygyno.2015.05.038.
Previs R, Leath CA, Coleman RL, Herzog TJ, Krivak TC, Brower SL, Tian C, Secord AA. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. Gynecol Oncol. 2015 Aug;138(2):267–271.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

August 2015

Volume

138

Issue

2

Start / End Page

267 / 271

Location

United States

Related Subject Headings

  • Young Adult
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Staging
  • Middle Aged
  • Humans
  • Female
  • Drug Resistance, Neoplasm
  • Drug Resistance, Multiple